GlassScriptPhysician profile
Gary T Roome
NPI 1376534396
$2,052.45
in general payments reported to CMS, 2019-2025
26 companies · $501 in 2025
The $501 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $463 · 2020: $78.24 · 2023: $305 · 2024: $705 · 2025: $501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,510.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $521.88 | 2019-2025 | Arexvy, Trelegy Ellipta, Bexsero |
| Otsuka America Pharmaceutical, INC. | $296.26 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Abbvie INC. | $222.08 | 2023-2025 | Vraylar, Mavyret |
| Astrazeneca Pharmaceuticals LP | $147.83 | 2023-2025 | Farxiga, Airsupra |
| Amgen INC. | $109.67 | 2019-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $103.96 | 2024-2025 | Ozempic, Rybelsus |
| Sunovion Pharmaceuticals INC. | $100.06 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $65.60 | 2019-2024 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $62.91 | 2023-2025 | Caplyta |
| Exact Sciences Corporation | $55.09 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Vanda Pharmaceuticals INC. | $39.02 | 2025 | Fanapt |
| Axsome Therapeutics, INC. | $36.46 | 2023 | Auvelity |
| Merck Sharp & Dohme LLC | $34.17 | 2019-2024 | M-M-R II, Capvaxive, Gardasil 9 |
| Pfizer INC. | $30.55 | 2019-2024 | |
| Lilly USA, LLC | $28.74 | 2019-2024 | Mounjaro, Zepbound |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $24.71 | 2025 | Aptima, Thinprep 2000 Processor |
| Avanir Pharmaceuticals, INC. | $22.57 | 2019 | |
| Sumitomo Pharma America, INC. | $22.31 | 2024 | Gemtesa |
| Dexcom, INC. | $21.67 | 2025 | Dexcom G6 Transmitter |
| Organon LLC | $20.93 | 2024 | |
| Alnylam Pharmaceuticals INC. | $19.59 | 2024 | Givlaari |
| Eisai INC. | $17.18 | 2019 | |
| Neurocrine Biosciences, INC. | $13.43 | 2020 | |
| Shire North American Group INC | $12.30 | 2019 | |
| Allergan, INC. | $12.07 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Roome listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.